Samsung Biologics (207940.KS)
Healthcare · KRX · Korea
Fundamentals
Valuation and ratings
Samsung Biologics trades at ₩1,396,000.00. We do not hold enough of the inputs to run a discounted cash flow on this company, so we publish no fair value for it rather than a number we would not defend.
Our moat model scores it 90 out of 100, which is a wide moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
About Samsung Biologics
Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing, commercializing, distributing, and selling of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offers aseptic filling, lyophilization, finishing, cold chain storage and shipping, and regulatory support services; and quality services and analytical testing services, such as IPC and release testing, stability study and testing, environmental monitoring, biosafety testing, as well as manufactures drug substance. In addition, it engages in the development and manufacture of antibody-drug conjugates and mRNA products. The company was founded in 2011 and is headquartered in Incheon, South Korea.
207940.KS passes 5 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
The full research page for 207940.KS, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.